INTRODUCTION {#S1}
============

*Acinetobacter baumannii* has been recognized over the last decades as a major pathogen that responsible for severe infections, especially in the Intensive Care Units (ICU) patients ([@R1], [@R2]). Ventilator-associated pneumonia (VAP) occurs in critically ill patients who admitted to ICU and *A.baumannii* frequently isolated in respiratory specimens of these patients ([@R2], [@R3]). VAP complications are increased mortality rate, prolonged hospitalization and high medical costs ([@R4], [@R5]). Although, previously, most of *A.baumannii* isolates were sensitive to carbapenems, and imipenem was the gold standard treatment for *A.baumannii* pneumonia ([@R1], [@R5]), widespread use of carbapenems has led to an emergence of resistant strains ([@R6]). Nowadays, carbapenem resistant *A. baumannii* (CRAB) has been reported worldwide, and it has became a global problem ([@R7]). In addition, an important concern is nosocomial infection causing by multidrug resistant *A. baumannii* (MDRAB) isolates ([@R8]). Due to increasing resistance, selection of an appropriate therapeutic option is difficult ([@R9]). The main mechanisms of carbapenem resistance in *A. baumannii,* is the production of carbapenem-hydrolyzing enzymes, mostly OXA types carbapenemases such as *bla*~OXA-23-like~, *bla*~OXA-24-like~, *bla*~OXA-58-like~ and *bla*~OXA-143-like~ and less common by metallo-β-lactamases ([@R7], [@R10]). In order to control and prevention of spread of resistant isolates, it is necessary to use a molecular method for typing of MDRAB *A. Baumannii* ([@R8]). Because no study has been performed independently solely on *A. baumannii* tracheal isolates in Ahvaz, this study was planned with the following objectives: (i) to study the antimicrobial susceptibility pattern (ii) to identify the most prevalent OXA types and metallo-β-lactamase genes and (iii) To characterize clonal relationship among *A. baumannii* isolates collected from the tracheal tube discharge in Ahvaz, south west of Iran using repetitive sequence-based polymerase chain reaction (REP-PCR).

MATERIALS AND METHODS {#S2}
=====================

Bacterial isolates {#S3}
------------------

This study was conducted at the 8 ICUs of 2 teaching hospitals, Imam Khomeyni and Golestan, associated to Ahvaz Jundishapur University of Medical Sciences from March 2010 to November 2012. A total of 206 *A. baumannii* isolates were collected from a tracheal tube discharge of ICUs patients which were colonized or infected by these bacteria. The patients were hospitalized in ICU sections such as: ICU internal, surgery, A & B, neurosurgical ICU (NSICU), general 1, general 2, cardiovascular ICU (CVICU). Initial identifications of *A. baumannii* were performed using standard laboratory tests([@R11]).

Antimicrobial susceptibility test {#S4}
---------------------------------

All isolates were subjected to antimicrobial susceptibility testing by standard disk diffusion method according to Clinical and Laboratory Standard Institute (CLSI) guidelines ([@R12]). The tested antimicrobial agents were as follows: imipenem 10 μg, meropenem 10 μg, polymyxin B 300 unit, gentamicin 10 μg, ceftriaxone 30 μg, colistin 10 μg, piperacillin 100 μg, piperacillin-tazobactam 100/10 μg, cefepime 30 μg tobramycin 10 μg, tigecyclin15 μg, amikacin 30 μg, tetracycline 30 μg, ciprofloxacin 5 μg, trimethoprim-sulfamethoxazole 1.25/23.75 μg, ceftazidime 30μg, rifampin 5 μg, aztreonam 30 μg and ampicillin-sulbactam (10/10 μg), (MAST, Group Ltd, Merseyside, UK). Reference strains include *Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853 were used for quality control testing ([@R12]). The results of disk diffusion were interpreted by CLSI. The US Food and Drug Administration-approved criteria for enterobacteriaceae used for tigecycline breakpoint ([@R13]).

Extraction of DNA {#S5}
-----------------

DNA was extracted by phenol--chloroform method with some modification. After growth of bacteria on Mueller-Hinton's agar plates, 2 or 3 colonies were suspended in 180 μl of distilled water. Then, 20 μl of proteinase K (1 mg/ml) was added and after adding 200 μl of buffer solution (0.5% SDS, 0.005 M EDTA and 0.01 M Tric-Cl, pH 7.8) mixture was incubated at 55°C for 2 hours. Then 200 μl of phenol and 200 μl of chloroform was added and gently mixed. After centrifugation at 11000 rpm for 5 minutes at 4°C, the supernatant was collected and transferred to a new tube carefully. To precipitate of DNA, 50 μl of ammonium acetate 7.5 M and 200 μl of absolute ethanol were added. DNA was removed and transferred to a new tube. After washing three times with 70% ethanol, DNA was placed at 30°C overnight. Dried DNA was dissolved in 100 μl of TE buffer([@R14]). The DNA purity of extracted was measured by photobiometer (Eppendorf, Germany) in 260/280 nm UV long waves.

Detection of *bla*~OXA-51-like~ {#S6}
-------------------------------

To confirm the identity of *A. baumannii*, *bla*~OXA-51-like~ gene was sought by PCR assay using specific primers listed in [Table 1](#T1){ref-type="table"}([@R15]). To amplify this gene, each reaction was carried out in a final volume of 25 μl containing 1x PCR buffer, 1U Taq polymerase, 1.5 mM MgCl~2~, 200 μM of dNTP (CinnaGen, Iran), 10 pmol of each primer (Eurofins MWG Operon, Germany) and 1 μl of extracted DNA. Amplification conditions were programmed in Mastercycler Eppendorf (Eppendorf, Germany) as follows: Initial denaturation at 94°C for 3 min; 35 cycles of 94°C for 45 s, annealing 57°Cfor 45 s, extension 72°C for 1min and final extension 72°C for 5 min. PCR products were separated on 1.5% agarose gel (CinnaGen, Iran) by electrophoresis, stained with ethidium bromide (CinnaGen, Iran) and then visualized under UV gel documentation system*. A*. *baumannii* NCTC 12156 (ATCC 19606) was used as positive control. A negative control was included in each PCR reaction, containing all components except the DNA template which was replaced by distilled water ([@R15], [@R16]).

Multiplex PCR for detection of oxacillinase genes {#S7}
-------------------------------------------------

*bla*~OXA-23-like~, *bla*~OXA-24-like~ and *bla*~OXA-58-like~ were sought for all isolates by multiplex PCR according to protocol as described previously ([@R15]). Each PCR reaction was performed in a final volume of 25 μl with 1x PCR buffer, 1U Taq polymerase, 2 mM MgCl~2~, 200 μM of dNTP (CinnaGen, Iran), 0.2 μM of each primer (TAG, Copenhagen A/S Denmark) and 1 μl of template DNA. PCR conditions were programmed in Mastercycler Eppendorf (Eppendorf, Germany) as follows: Initial denaturation at 94°C for 5 min; followed by 30cycles at 94°C for 30 s, 53°C for 40 s and 72°C for 50s and final extension at 72°C for 6 min. PCR products were separated with electrophoresis on 1.5% agarose gel (Cinna Gen, Iran) and after staining with ethidium bromide, visualized under UV gel documentation system. *A. baumannii* reference strains including NCTC 13304, NCTC 13302, NCTC 13305 used as positive control for *bla*~OXA-23-like~, *bla*~OXA-24-like~ and *bla*~OXA-58-like~, respectively ([@R15]).

Detection of metallo ß-lactamase genes {#S8}
--------------------------------------

he presence of different metallo ß-lactamase encoding genes such as: *bla*~IMP~, *bla*~VIM~, *bla*~SPM~ and *bla*~NDM~ were investigated by PCR with specific primers that were listed in ([Table 1](#T1){ref-type="table"}) and protocol from two previous studies ([@R16], [@R17]).

REP-PCR {#S9}
-------

In order to determine genetic relationship of carbapenem resistant *A.baumannii*, REP-PCR was carried out on all isolates with specific primers previously described ([@R18]) and are listed in ([Table 1](#T1){ref-type="table"}). Amplification condition was performed based on the method of Bou *et al.* with some modifications ([@R14]). Each reaction mixture was done in volume of 25 μl with 1x PCR buffer, 3.5 mM of MgCl~2~, 300 μM of dNTP, 3% DMSO (Cinna Gen, Iran), 0.5 μM of each primer (TAG, Copenhagen A/S Denmark), and 1U of Taq polymerase and 1 μl of genomic DNA. PCR conditions were as follows: 94°C for 10 min; 30 cycles of 94°C for 1 min, annealing temperatures 45°C for 1 min and 72°C for 2 min and 72°C for 16 min. Products were separated with electrophoresis on 1.2% agarose gel (CinnaGen, Iran); after staining with ethidium bromide, they were visualized under UV gel documentation system; then they were photographed and compared together with visual inspection ([@R14]). All fingerprints were observed by one observer. Fingerprints were interpreted according to previous studies ([@R18], [@R19]).

Statistical analysis {#S10}
--------------------

The results were analyzed using the SPSS version 16 to obtain frequencies and comparison among clones. Non parametric Chi-square test was used (X^2^ = 156.6, df = 5). A *P*-value \< 0.001 was considered statistically significant.

RESULTS {#S11}
=======

Bacterial isolates and antimicrobial susceptibility pattern {#S12}
-----------------------------------------------------------

The rates of isolation from different wards were as follows: ICU Internal (41.3%), Surgery (14.1%), B (13.1%), Neurosurgical Intensive Care Unit NICU (9.2%), A (7.8%), General 1 (5.3%), General 2 (7.8%), Cardiovascular Intensive Care Unit (CVICU) (1.5%). All 206 studied isolates contained *bla*~Oxa-51-like~ gene and were known as *A. baumannii*. All isolates (100%) were susceptible to colistin and polymyxin B. Maximum resistance rate was observed for aztreonam and rifampin with 98.5% and 98.1%, respectively. The rate of resistance to antimicrobial agents is shown in [Table 2](#T2){ref-type="table"}.

Detection of Oxacillinase and Metallo-β-lactamase {#S13}
-------------------------------------------------

Results of multiplex PCR showed the *bla*~OXA-23-like~and *bla*~OXA-24-like~ genes were detected in 85% and 8.7%, respectively ([Fig. 1](#F1){ref-type="fig"}). Six isolates were carbapenem resistant but these isolates were negative for *bla*~OXA-23-like~, *bla*~OXA-24-like~, *bla*~OXA-58-like~ and studied metallo-β-lactamase genes. No *bla*~OXA-58-like~, *bla*~IMP~, *bla*~VIM~, *bla*~SPM~ and *bla*~NDM~ were detected. *bla*~OXA-23-like~, *bla*~OXA-24-like~and *bla*~OXA-58-like~*bla*~IMP~, *bla*~VIM~, *bla*~SPM~ and *bla*~NDM~ were not detected in carbapenem susceptible *A. baumannii* (CSAB) isolates.

REP-PCR {#S14}
-------

To determine the genetic relationship, all isolates were analyzed by REP-PCR. According to the REP-PCR results, carbapenem resistant isolates were grouped into five clones. The first prevalent genotype was named genotype A and was observed in 75 (36.4%) of 206 isolates (*P*- value \< 0.001), thereafter 59 isolates (28.6%) and 57 isolates (27.7%) belonged to genotypes B and C, respectively, ([Fig. 2](#F2){ref-type="fig"}). The rates of other genotypes were as follows: D: 5 (2.4%), E: 2 (1%). All clones were distributed throughout the study period. Albeit *bla*~OXA-23-like~ was found in all clones, *bla*~OXA-24-like~ was seen only in clones A, B, C and D, but clones E was negative for this gene. Eight isolates (3.9%) were carbapenem susceptible and showed different REP pattern from each other. Frequency of each clone in different ICUs was presented in [Table 3](#T3){ref-type="table"}.

DISCUSSION {#S15}
==========

*A. baumannii* is the third causative agent of infection at ICUs patients with mortality rates of 26-68% ([@R20]). Increasing rate of carbapenems resistant *A. baumannii* is an important concern ([@R7]). Production of Class D oxacillinase which is distributed worldwide is the main mechanism of resistance to carbapenems in this organism. The major carbapenemase genes involved in carbapenem resistance are *bla*~OXA-23-like~, *bla*~OXA-24-like~, *bla*~OXA-58-like~and *bla*~OXA-143-like~. The *bla*~OXA-51-like~genes are located in chromosome of all *A. baumannii* strains and are intrinsic to this species ([@R1], [@R21], [@R22]). In sporadic case or hospital outbreaks of imipenem-resistant, OXA producing *A. baumannii* has been described worldwide ([@R1]). Distribution of OXA genes is variable. The rate of *bla*~OXA-23-like~has been reported from 31% to 94% in different parts of the world ([@R8],[@R10],[@R23]-[@R25]). Our result for *bla*~Oxa-23-like(~85%) is in the reported ranges. We found 8.7% of isolates were positive for *bla*~Oxa-24-like.~ However, the prevalence rate of this gene has been shown previously from 0 to 85.43% ([@R6],[@R10],[@R16]-[@R24]). Despite some authors reported *bla*~OXA-58-like~from 2% to 84.92% in *A. Baumannii* ([@R8], [@R23], [@R25], [@R26]) but we did not find any *bla*~OXA-58-like~gene in accordance with previous studies ([@R6], [@R10], [@R24]). Interestingly, we identified 6 isolates that were resistant to imipenem and meropenem that possessed only the intrinsic *bla*~OXA-51-like~, but other investigated genes were negative. Resistance to carbapenems in these isolates may be in related to other mechanisms including decreased permeability, alteration of penicillin-binding proteins, AmpC stable derepression and overexpression of efflux pump ([@R27]). In *A. baumannii*, metallo-β-lactamase genes such as: *bla*~IMP~, *bla*~VIM~, *bla*~SPM~ and *bla*~NDM~, have been reported sporadically ([@R28]-[@R32]) but we did not find any of these genes in our isolates. Similar to our results, negative finding for *bla*~IMP~, *bla*~VIM~ *bla*~SPM~ and *bla*~NDM~ has been reported by some authors ([@R6], [@R8], [@R24], [@R33]). REP-PCR revealed three main genotypes are present in our hospitals and 92.7% of isolates belonged to three genotypes A, B and C. Nosocomial outbreaks of carbapenem resistant *A. baumannii* were reported worldwide and in most cases one or two epidemic isolates were involved ([@R34]) and certain clones are disseminated in the hospitals ([@R8], [@R24], [@R35]). Since, the majority of our isolates belonged to three main genotypes, it is possible that cross-transmission with similar organisms has been occurred between patients. Therefore, it seems that these clones are circulating in our hospitals. Yan *et al.* reported that multidrug resistant *A. baumannii* from same genotype can be transferred between hospitals and even cities ([@R8]). Albeit *bla*~Oxa-23-like~ was found among all resistant clones, interestingly only genotypes A, B, C and D were positive for *bla*~Oxa-24-like~ and this gene was negative in genotypes E. Of note, each sensitive isolates had unique REP-PCR patterns that were different from carbapenem resistant isolates and it is assumed that probable source of this isolates were outside of the studied hospitals. However, it has been reported that carbapenem susceptible isolates may have highly similar or different REP pattern from the carbapenem resistant isolates ([@R35]). Our finding revealed that in addition to carbapenems, the rates of resistance to other antimicrobial agents were high. Dizbay *et al.* 2008 in Turkey studied on susceptibility pattern of 66 isolates of *A. baumannii* collected from endotracheal aspirate and found resistance rate to imipenem, and meropenem was 80.3% and 71.2%, respectively. Different rate of resistance to other tested antibiotics were reported by Dizbay et al. ([@R9]). The rates of resistance to all antimicrobial agents in our study are higher than reported by Dizbay *et al*.

In conclusion, REP-PCR revealed that three main genotypes involved in the two studied hospitals. In order to prevent the spread of resistant isolates between different wards and patients, we suggest it is necessary to monitor and improve infection-control procedures. Although the research was carefully performed and was reached its aims, but there was one limitation. In our study, difference between colonization and infection was not clear and it suggested that in future studies this subject be surveyed.
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![Electrophoresis results of multiplex PCR. Lanes 1 and 14: 100bp DNA ladder. Lanes 2, 7, 8: isolates with *bla*~OXA-24-like~ in 249 bp. Lanes 3, 4, 5, 9 & 10: isolates with *bla*~OXA-23-like~ in 501 bp. Lanes 6 & 11 isolates that are negative for *bla*~OXA-23-like~, *bla*~OXA-24-like~ and *bla*~OXA-58-like~. Lane 12 negative control (distilled water ) and lane 13 Positive control (*A. baumannii* NCTC 13304, NCTC 13302, NCTC 13305 used as positive control for *bla*~OXA-23-like~, *bla*~OXA-24-like~ and *bla*~OXA-58-like~ respectively.](IJM-5-315f1){#F1}

![Electrophoresis of REP-PCR products for three major clone of CRAB. Double fingerprints have been shown for each isolate. Lanes 1, 6 , 11, 1 kb DNA ladder. Lanes 2, 3 (clone A), lanes 4, 5 (clone B), lanes 7, 8 (clone C), Lane 9, negative control and lane 10, *A. baumannii*NCTC 12156 (ATCC 19606).](IJM-5-315f2){#F2}

###### 

Primers sequences used in this study.

  Primer name                Sequence ( 5'-3')        Amplicon size ( bp)   Reference
  -------------------------- ------------------------ --------------------- -----------
  *bla*~OXA-51-\ like~ - F   TAATGCTTTGATCGGCCTTG     353                   ([@R16])
  *bla*~OXA-51-\ like~ -R    TGGATTGCACTTCATCTTGG                           
  *bla*~OXA-23-\ like~-F     GATCGGATTGGAGAACCAGA     501                   
  *bla*~OXA-23-\ like~-R     ATTTCTGACCGCATTTCCAT                           
  *bla*~OXA-24-\ like~-F     GGTTAGTTGGCCCCCTTAAA     249                   
  *bla*~OXA-24-\ like~-R     AGTTGAGCGAAAAGGGGATT                           
  *bla*~OXA-58-\ like~F      AAGTATTGGGGCTTGTGCTG     599                   
  *bla*~OXA-58-\ like~-R     CCCCTCTGCGCTCTACATAC                           
  *bla*~IMP~-F               TCGTTTGAAGAAGTTAACGG     568                   ([@R18])
  *bla*~IMP~-R               ATGTAAGTTTCAAGAGTGATGC                         
  *bla*~VIM~-F               GGTGTTTGGTCGCATATCGCAA   502                   
  *bla*~VIM~-R               ATTCAGCCAGATCGGCATCGGC                         
  *bla*~NDM~- F              GGTTTGGCGATCTGGTTTTC     624                   ([@R17])
  *bla*~NDM~-R               CGGAATGGCTCATCACGATC                           
  *bla*~SPM~-F               AAAATCTGGGTACGCAAACG     271                   
  *bla*~SPM~-R               ACATTATCCGCTGGAACAGG                           
  REP-1                      IIIGCGCCGICATCAGGC                             ([@R19])
  REP-2                      ACGTCTTATCAGGCCTAC                             

###### 

The results of antibiogram test for *A.baumannii* isolates.

  Antibiotic                                                            
  --------------------------------------------- ----------- ----------- ------------
  Imipenem 10 μg                                8 (3.9)     \-          198(96.1)
  Meropenem 10 μg                               8 (3.9)     \-          198 (96.1)
  Ceftazidime 30 μg                             7 (3.4)     1 (0.5)     198 (96.1)
  Cefepime 30 μg                                8 (3.9)     \-          198 (96.1)
  Ceftriaxone 30 μg                             1 (0.5)     7 (3.4)     198 (96.1)
  Colistin 10 μg                                206 (100)   0           0
  Piperacillin 100 μg                           6 (2.9)     1 (0.5)     199 (96.6)
  Piperacillin-tazobactam 100/10 μg             8 (3.9)     0           198 (96.1)
  Polymyxin B 300 unit                          206 (100)   0           0
  Gentamicin 10 μg                              33 (16)     2 (1)       171 (83)
  Tobramycin 10 μg                              44( 21.4)   0           162 (78.6)
  Amikacin 30 μg                                13 (6.3)    10 (4.9)    183 (88.8)
  Tetracycline 30 μg                            15 (7.3)    16 (7.8)    175 (85)
  Ampicillin-sulbactam 10/10 μg                 34 (16.5)   29 (14.1)   143 (69.4)
  Ciprofloxacin 5 μg                            7 (3.4)     0           199 (96.6)
  Trimethoprim-sulfamethoxazole 1.25/23.75 μg   16 (7.8)    5 (2.4)     185 (89.8)
  Rifampin 5 μg                                 0           4 (1.9)     202 (98.1)
  Aztreonam 30 μg                               0           3 (1.5)     203 (98.5)
  Tigecycline 15 μg                             13 (6.3)    66 (32)     127 (61.7)

###### 

Frequency of each clone of carbapenem resistant and carbapenems susceptible isolates in different ICUs.

  ICU                                                
  ----------- ---- ---- ---- ---- ---- ---- ---- --- -----
  A           36   7    5    9    6    1    9    2   75
  B           31   10   1    3    4    6    3    1   59
  C           11   8    9    14   8    4    3    0   57
  D           2    2    0    0    0    0    1    0   5
  E           1    1    0    0    0    0    0    0   2
  Sensitive   4    1    1    1    1    0    0    0   8
  Total       85   29   16   27   19   11   16   3   206

Neurosurgical ICU

Cardiovascular ICU
